Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
claudin-4 antibody
- Development stage
- Preclinical
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Claudin-4 is a member of the claudin family of tight junction proteins, which are frequently overexpressed in various epithelial malignancies, including ovarian, pancreatic, and gastric cancers. Antibodies targeting Claudin-4 are being investigated for their potential as both diagnostic biomarkers and therapeutic agents. In a therapeutic context, anti-Claudin-4 antibodies may function through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or as part of antibody-drug conjugates (ADCs) to deliver cytotoxic payloads specifically to tumor cells. In research and diagnostics, these antibodies are used in immunohistochemistry (IHC) to assess Claudin-4 expression levels, which has been linked to prognosis and therapy resistance in cancers such as epithelial ovarian cancer.
- Other names
- anti-Claudin-4 antibodyanti-Claudin4 antibodyanti-Claudin 4 antibodyanti-CLDN4 antibodyanti-CLDN-4 antibodyanti-CLDN 4 antibody
02
Targets
CLDN4 (Claudin-4)
Beyond the preview
Go deeper on claudin-4 antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on claudin-4 antibody.